This study looked at the association between breast cancer (BC) prognosis and statin use. The authors found that statin use is associated with a reduced recurrence and mortality in women with BC. 

This study was carried to examine the effectiveness of using chest computed tomography (CT) for the screening of osteoporosis (OP) and predicting the risk of fractures (bone breaks) in patients with breast cancer (BC). The authors found that CT can be used for predicting OP and determining the risk of fractures in these patients. 

This trial was carried out to assess the effectiveness and safety of veliparib (ABT-888) in combination with carboplatin (Paraplatin) and paclitaxel (Taxol) in BRCA-mutated advanced breast cancer (BC). The authors found that the addition of veliparib to platinum-based chemotherapy resulted in an improved survival without disease progression. 

This study wanted to find out if taking pictures of lymph nodes using medical imaging techniques helped in finding out if treatment for lymph node swelling was working. The study found that using lymphoscintigraphy helped in evaluating the treatment of lymph node swelling. 

This review aimed to summarize available data about the effectiveness of mindfulness-based interventions for cancer-related symptoms in cancer patients and survivors.  

This review concluded that mindfulness-based interventions can have a beneficial effect as an adjuvant therapy in these patients.  

This study wanted to find out how well chemotherapy for invasive breast cancer works, especially in those over 70 years old. The study found that most patients benefit from chemotherapy, however, those aged over 70 benefited less of this treatment than those aged under 70.

This study investigated if there is a higher risk of cardiovascular disease (CVD) in cancer survivors. They found that cancer survivors have a higher risk of CVD.

This study investigated the effectiveness of alpelisib (Piqray) in hormone receptor-positive (HR+) -human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC).

They found that alpelisib significantly improved survival in patients with PIK3CA mutations. 

This study investigated the risk of fatigue and anemia with olaparib (Lynparza) treatment. The study found that there is an increased risk of fatigue and anemia with this treatment.

This study wanted to find out how well patients with hormone-receptor-positive breast cancer survived when treated with ribociclib (Kisqali) added to endocrine therapy. The study found that patients treated with this treatment combination had longer survival compared to endocrine therapy alone.